GlassScriptPhysician profile
Lacey Steinwand
NPI 1427710276
$3,498.30
in general payments reported to CMS, 2019-2025
26 companies · $903 in 2025
The $903 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $504 · 2023: $790 · 2024: $1,302 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,994.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $787.70 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $721.49 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $560.60 | 2023-2025 | |
| Glaxosmithkline, LLC. | $325.20 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $119.78 | 2022-2025 | Repatha, Otezla, Aimovig |
| Otsuka America Pharmaceutical, INC. | $114.17 | 2023-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $103.61 | 2024-2025 | Austedo Xr, Austedo Xr |
| Novo Nordisk INC | $102.62 | 2023-2025 | Ozempic, Rybelsus |
| Mylan Specialty L.P. | $82.30 | 2022-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $81.28 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.78 | 2022-2023 | |
| Lilly USA, LLC | $58.68 | 2022-2023 | Jardiance, Emgality |
| Exact Sciences Corporation | $58.17 | 2023-2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $44.07 | 2024 | Gemtesa |
| Axsome Therapeutics, INC. | $38.71 | 2025 | Auvelity, Symbravo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $36.78 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.24 | 2024 | Jardiance |
| Averitas Pharma INC. | $24.85 | 2023 | Qutenza |
| Braeburn INC. | $19.26 | 2023 | Brixadi |
| Idorsia Pharmaceuticals US INC | $18.30 | 2022 | |
| Astellas Pharma US INC | $18.11 | 2023 | Veozah |
| Indivior INC. | $17.30 | 2023 | Sublocade |
| Boston Scientific Corporation | $15.37 | 2024 | Watchman Flx |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.15 | 2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $14.15 | 2023 | Spravato |
| Lundbeck LLC | $13.63 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacey Steinwand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.